Articles
12 June 2009
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
https://doi.org/10.4081/hmr.v3i3.559

The role of thalidomide as maintenance after autologous stem-cell transplantation in multiple myeloma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
199
Views
204
Downloads

Authors

A Maiolino
support@pagepress.org
V Tietsche de Moraes Hungria
M Nucci
C De Souza
Major progress was obtained in the last ten years for treatment of multiple myeloma (MM). High dose chemotherapy with autologous stem – cell transplant (ASCT) and new drugs as thalidomide, lenalidomide and bortezomibe have completely changed the scenario of MM treatment. ASCT becomes the mainstay of MM treatment for patients up to 65 years old. This strategy has been tested in randomized clinical trials and it proven that ASCT can improve overall survival of MM patients. Unfortunately, the large majority of these patients will relapse in few years after ASCT. Strategies of maintenance were developed trying to improve the ASCT results. Thalidomide has been tested in this setting on at least 4 randomized clinical trials with a significant impact on response rate, event free and overall survival.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



The role of thalidomide as maintenance after autologous stem-cell transplantation in multiple myeloma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.559